Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma

Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma

Podoplanin (PDPN), a small transmembrane mucin-like glycoprotein, is ectopically expressed on tumor cells. PDPN is known to be linked with several aspects of tumor malignancies in certain types of human and canine tumors. Therefore, it is considered to be a novel therapeutic target. Monoclonal antib...

Full description

Bibliographic Details
Main Authors: Satoshi Kamoto, Masahiro Shinada, Daiki Kato, Sho Yoshimoto, Namiko Ikeda, Masaya Tsuboi, Ryohei Yoshitake, Shotaro Eto, Yuko Hashimoto, Yosuke Takahashi, James Chambers, Kazuyuki Uchida, Mika K. Kaneko, Naoki Fujita, Ryohei Nishimura, Yukinari Kato, Takayuki Nakagawa
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cells
Subjects:
podoplanin
dog
antibody therapy
tumor
melanoma
Online Access:https://www.mdpi.com/2073-4409/9/11/2529

Internet

https://www.mdpi.com/2073-4409/9/11/2529

Similar Items